ArticleJournal of veterinary pharmacology and therapeutics2026
Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.
Article in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment.Pharmaceutics · 2026Article
- Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis.Veterinary sciences · 2026Review
- Epidemiological and Clinical Characterization of Atopic Dermatitis in Dogs from Quito, Ecuador: Retrospective Analysis of Cases (2018-2025).Veterinary sciences · 2026Article
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.4 to 4.0 mg/kg, and multiple dosing was evaluated with daily oral doses of 0.8 mg/kg. Serial blood samples were collected, and plasma concentrations of ilunocitinib were measured using a validated LC-MS/MS method. Pharmacokinetic samples were also collected in field trials. Intravenous administration resulted in low plasma clearance (0.437 L/h/kg), a volume of distribution of 1.58 L/kg, and a terminal half-life of 4.4 h. Oral administration led to rapid absorption (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.